Granisetron Ratiopharm (Granisetron)

Granisetron Ratiopharm is indicated for the prevention of nausea and vomiting in specific clinical settings.

• Prevention of chemotherapy‑induced nausea and vomiting (CINV) in adult patients.
• Prevention of postoperative nausea and vomiting (PONV) following surgical procedures.
• Use as part of a multimodal antiemetic regimen when high emetogenic risk is anticipated.
• Management of nausea associated with radiotherapy in patients receiving moderate to high dose treatments.
• Adjunct therapy for nausea related to other serotonergic triggers when clinically appropriate.

The safety profile of Granisetron Ratiopharm includes a range of observed adverse events, most of which are mild and transient.

Common

• Headache
• Constipation or mild abdominal discomfort
• Dizziness or light‑headed feeling
• Fatigue

Serious

• Severe allergic reaction (anaphylaxis, rash, swelling)
• Cardiac arrhythmias or QT interval prolongation
• Persistent severe constipation leading to bowel obstruction

Before prescribing Granisetron Ratiopharm, clinicians should evaluate patient history and consider several precautionary factors to minimize risk.

• Assess for known hypersensitivity to granisetron or other 5‑HT3 antagonists.
• Use cautiously in patients with a history of cardiac conduction disorders or prolonged QT interval.
• Evaluate renal and hepatic function, as dose adjustments may be needed in severe impairment.
• Monitor for signs of severe constipation, especially in patients with gastrointestinal motility disorders.
• Consider pregnancy and breastfeeding status; safety data are limited.
• Review concomitant medications that may affect cardiac rhythm.

Granisetron Ratiopharm can interact with other drugs, and certain combinations should be avoided or used with careful monitoring.

Avoid

• Other medications known to prolong the QT interval (e.g., certain antiarrhythmics, antipsychotics, macrolide antibiotics).
• Strong CYP3A4 inhibitors that may increase granisetron plasma levels (e.g., ketoconazole, itraconazole).

Use with caution

• Drugs that affect cardiac conduction (e.g., digoxin, certain anti‑emetics).
• Medications that may cause additive constipation (e.g., opioids, anticholinergics).
• Concurrent use of other serotonergic agents, monitoring for serotonin syndrome.